{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:48:07Z","timestamp":1787701687923,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA041613"],"award-info":[{"award-number":["DA041613"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA041613"],"award-info":[{"award-number":["DA041613"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP1DA042103"],"award-info":[{"award-number":["DP1DA042103"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cocaine use presents a worldwide public health problem with high socioeconomic cost. No current pharmacologic treatments are available for cocaine use disorder (CUD) or cocaine toxicity. To explore pharmaceutical treatments for tthis disorder and its sequelae we analyzed gene expression data from post-mortem brain tissue of individuals with CUD who died from cocaine-related causes with matched cocaine-free controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200971,\n                    <jats:italic>M<\/jats:italic>\n                    <jats:sub>age<\/jats:sub>\n                    \u2009=\u200939.9, 100% male, 49% with CUD, 3 samples\/brain regions). To match molecular signatures from brain pathology with potential therapeutics, we leveraged the L1000 database honing in on neuronal mRNA profiles of 825 repurposable compounds (e.g., FDA approved). We identified 16 compounds that were negatively associated with CUD gene expression patterns across all brain regions (\n                    <jats:italic>p<\/jats:italic>\n                    <jats:sub>adj<\/jats:sub>\n                    \u2009&lt;\u20090.05), all of which outperformed current targets undergoing clinical trials for CUD (all\n                    <jats:italic>p<\/jats:italic>\n                    <jats:sub>adj<\/jats:sub>\n                    \u2009&gt;\u20090.05). An additional 43 compounds were positively associated with CUD expression. We performed an\n                    <jats:italic>in silico<\/jats:italic>\n                    follow-up potential therapeutics using independent transcriptome-wide in vitro (neuronal cocaine exposure; n\u2009=\u200918) and in vivo (mouse cocaine self-administration;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912\u201315) datasets to prioritize candidates for experimental validation. Among these medications, ibrutinib was consistently linked with the molecular profiles of both neuronal cocaine exposure and mouse cocaine self-administration. We assessed the therapeutic efficacy of ibrutinib using the\n                    <jats:italic>Drosophila melanogaster<\/jats:italic>\n                    model. Ibrutinib reduced cocaine-induced startle response and cocaine-induced seizures (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200961\u2013142 per group; sex: 51% female), despite increasing cocaine consumption. Our results suggest that ibrutinib could be used for the treatment of cocaine use disorder.\n                  <\/jats:p>","DOI":"10.1038\/s41398-021-01737-5","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T13:15:35Z","timestamp":1638969335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ibrutinib as a potential therapeutic for cocaine use disorder"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-7011","authenticated-orcid":false,"given":"Spencer B.","family":"Huggett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-9647","authenticated-orcid":false,"given":"Jeffrey S.","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"McGeary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-744X","authenticated-orcid":false,"given":"Justine W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy F. C.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7196-8324","authenticated-orcid":false,"given":"Robert R. H.","family":"Anholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-9962","authenticated-orcid":false,"given":"Rohan H. C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"1737_CR1","unstructured":"United Nations Publication SNE 19. X 8. World drug report. United Nations Publication; 2019."},{"key":"1737_CR2","unstructured":"SAMSHA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. 2019."},{"key":"1737_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.drugalcdep.2017.12.030","volume":"185","author":"C Turner","year":"2019","unstructured":"Turner C, Chandrakumar D, Rowe C, Santos G, Riley D, Coffin PO. Cross-sectional cause of death comparisons for stimulant and opioid mortality in San Francisco, 2005\u20132015. Drug Alcohol Depend. 2019;185:305\u201312.","journal-title":"Drug Alcohol Depend"},{"key":"1737_CR4","unstructured":"National Institute on Drug Abuse [Internet]. Trends & Statistics: Overdose death rates [updated Jan 29 2021; cited Feburary 5, 2021]. Available from: https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates."},{"key":"1737_CR5","first-page":"3989","volume":"14","author":"L Dutra","year":"2006","unstructured":"Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of pyschosocial interventions for substance use disorders. Am J Pyschiatry. 2006;14:3989\u201396.","journal-title":"Am J Pyschiatry"},{"key":"1737_CR6","first-page":"2858","volume":"24","author":"B Chan","year":"2017","unstructured":"Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder\u2014a systematic review and meta-analysis. J Gen Intern Med. 2017;24:2858\u20132873.","journal-title":"J Gen Intern Med"},{"key":"1737_CR7","first-page":"122","volume":"67","author":"MP Vroegop","year":"2009","unstructured":"Vroegop MP, Franssen EJ, Voort PHJ, van den Berg TNA, Langewag RJ, Kramers C. The emergency care of cocaine intoxications. Neth J Med. 2009;67:122\u2013126.","journal-title":"Neth J Med"},{"key":"1737_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bcp.12720","volume":"81","author":"H Chen","year":"2015","unstructured":"Chen H, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharm. 2015;81:412\u20139.","journal-title":"Br J Clin Pharm"},{"key":"1737_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4155\/fmc.11.194","volume":"4","author":"D Narasimhan","year":"2012","unstructured":"Narasimhan D, Woods JH, Sunahara RK. Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction. Future Med Chem. 2012;4:137\u201350.","journal-title":"Future Med Chem"},{"key":"1737_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"EA Ribeiro","year":"2017","unstructured":"Ribeiro EA, Scarpa JR, Garamszegi SP, Kasarskis A, Mash DC, Nestler EJ. Gene network dysregulation in dorsolateral prefrontal cortex neurons of humans with cocaine use disorder. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"1737_CR11","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1073\/pnas.1018514108","volume":"108","author":"Z Zhou","year":"2011","unstructured":"Zhou Z, Yuan Q, Mash DC, Goldman D. Substance-specific and shared transcription and epigenetic changes in the human hippocampus chronically exposed to cocaine and alcohol. Proc Natl Acad Sci. 2011;108:6626","journal-title":"Proc Natl Acad Sci"},{"key":"1737_CR12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/npp.2014.70","volume":"39","author":"MJ Bannon","year":"2014","unstructured":"Bannon MJ, Johnson MM, Michelhaugh SK, Hartley ZJ, Halter SD, David JA, et al. A molecular profile of cocaine abuse includes the differential expression of genes that regulate transcription, chromatin, and dopamine cell phenotype. Neuropsychopharmacology. 2014;39:2191\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"1737_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/npp.2017.301","volume":"43","author":"LB Ferguson","year":"2018","unstructured":"Ferguson LB, Ozburn AR, Ponomarev I, Metten P, Reilly M, Crabbe JC, et al. Genome-wide expression profiles drive discovery of novel compounds that reduce binge drinking in mice. Neuropsychopharmacology. 2018;43:1257\u201366.","journal-title":"Neuropsychopharmacology"},{"key":"1737_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N. New tricks for old drugs. Nature 2016;534:314\u20136.","journal-title":"Nature"},{"key":"1737_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Root DE, Wong B, Golub TR, et al. A next generation connectivity map: L1000 platform resource. Cell. 2017;171:1437\u2013e17.","journal-title":"Cell"},{"key":"1737_CR16","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1523\/JNEUROSCI.2879-19.2020","volume":"40","author":"SB Huggett","year":"2020","unstructured":"Huggett SB, Stallings MC. Genetic architecture and molecular neuropathology of human cocaine addiction. J Neurosci. 2020;40:5300\u201313.","journal-title":"J Neurosci"},{"key":"1737_CR17","first-page":"1","volume":"25","author":"SB Huggett","year":"2019","unstructured":"Huggett SB, Stallings MC. Cocaine\u2019omics: Genome\u2010wide and transcriptome\u2010wide analyses provide biological insight into cocaine use and dependence. Addict Biol. 2019;25:1\u201310.","journal-title":"Addict Biol"},{"key":"1737_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"1737_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tp.2015.158","volume":"5","author":"N Fernandez-Castillo","year":"2015","unstructured":"Fernandez-Castillo N, Cabana-Dominguez J, Soriano J, Sanchez-Mora C, Roncero C, Grau-Lopez L, et al. Transcriptomic and genetic studies identify NFAT5 as a candidate gene for cocaine dependence. Transl Psychiatry. 2015;5:1\u20139.","journal-title":"Transl Psychiatry"},{"key":"1737_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.biopsych.2018.04.009","volume":"84","author":"DM Walker","year":"2018","unstructured":"Walker DM, Cates HM, Loh YE, Purushothaman I, Ramakrishnan A, Cahill KM, et al. Cocaine self-administration alters transcriptome-wide responses in the brain\u2019s reward circuitry. Biol Psychiatry. 2018;84:867\u201380.","journal-title":"Biol Psychiatry"},{"key":"1737_CR21","doi-asserted-by":"publisher","first-page":"e1007834","DOI":"10.1371\/journal.pgen.1007834","volume":"15","author":"CA Highfill","year":"2019","unstructured":"Highfill CA, Baker BM, Stevens SD, Anholt RRH, Mackay TFC. Genetics of cocaine and methamphetamine consumption and preference in Drosophila melanogaster. PLoS Genet. 2019;15:e1007834.","journal-title":"PLoS Genet"},{"key":"1737_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00439-012-1146-6","volume":"131","author":"KR Kaun","year":"2012","unstructured":"Kaun KR, Devineni AV, Heberlein U. Drosophila melanogaster as a model to study drug addiction. Hum Genet. 2012;131:959\u201375.","journal-title":"Hum Genet"},{"key":"1737_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nature14431","volume":"521","author":"KH Wang","year":"2015","unstructured":"Wang KH, Penmatsa A, Gouaux E. Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature. 2015;521:322\u20137.","journal-title":"Nature"},{"key":"1737_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0960-9822(98)70041-7","volume":"8","author":"C Mcclung","year":"1998","unstructured":"Mcclung C, Hirsh J. Stereotypic behavioral responses to free-base cocaine and the development of behavioral sensitization in Drosophila. Curr Biol. 1998;8:109\u201312.","journal-title":"Curr Biol"},{"key":"1737_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2018.00025","volume":"11","author":"A Filo\u0161evi\u0107","year":"2018","unstructured":"Filo\u0161evi\u0107 A, Al-samarai S, Andreti R. High throughput measurement of locomotor sensitization to volatilized cocaine in Drosophila melanogaster. Front Mol Neurosci. 2018;11:1\u201312.","journal-title":"Front Mol Neurosci"},{"key":"1737_CR26","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"1","author":"RA de Claro","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. FDA Approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;1:3586\u201391.","journal-title":"Clin Cancer Res"},{"key":"1737_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41587-020-00790-7","volume":"39","author":"E Dolgin","year":"2021","unstructured":"Dolgin E. BTK blockers make headway in multiple sclerosis. Nat Biotechnol. 2021;39:3\u20135.","journal-title":"Nat Biotechnol"},{"key":"1737_CR28","doi-asserted-by":"publisher","first-page":"25332","DOI":"10.18632\/oncotarget.25011","volume":"9","author":"MI Merolle","year":"2018","unstructured":"Merolle MI, Ahmed M, Nomie K, Wang ML. The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget. 2018;9:25332\u201341.","journal-title":"Oncotarget"},{"key":"1737_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/mp.2014.177","volume":"20","author":"AL Northcutt","year":"2015","unstructured":"Northcutt AL, Hutchinson MR, Wang X, Baratta MV, Hiranita T, Cochran TA. et al. DAT isn\u2019t all that: cocaine reward and reinforcement require Toll-like receptor 4 signaling. Mol Psychiatry. 2015;20:1525\u20131537.","journal-title":"Mol Psychiatry"},{"key":"1737_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/syn.890140210","volume":"14","author":"ND Volkow","year":"1993","unstructured":"Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, Dewey SL, Wolf AP. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14:169\u201377.","journal-title":"Synapse"},{"key":"1737_CR31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.biopsych.2011.06.010","volume":"70","author":"RJ Smith","year":"2011","unstructured":"Smith RJ, Aston-jones G. Alpha-2 adrenergic and imidazoline receptor agonists prevent cue-induced cocaine-seeking. Biol Psychiatry. 2011;70:712\u20139.","journal-title":"Biol Psychiatry"},{"key":"1737_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0006-3223(00)00229-8","volume":"47","author":"J Vandergriff","year":"2000","unstructured":"Vandergriff J, Kallman MJ, Rasmussen K. Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats. Biol Psychiatry. 2000;47:874\u20139.","journal-title":"Biol Psychiatry"},{"key":"1737_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2010.03.058","volume":"637","author":"BG Taksande","year":"2010","unstructured":"Taksande BG, Kotagale NR, Patel MR, Shelkar GP, Ugale RR, Chopde CT. Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharm. 2010;637:89\u2013101.","journal-title":"Eur J Pharm"},{"key":"1737_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.2174\/1389450111314070006","volume":"14","author":"B Le Foll","year":"2013","unstructured":"Le Foll B, Di Ciano P, Panlilio LV, Goldberg SR, Ciccocioppo R. Agonists as promising new medications for drug addiction: evidence. Curr Drug Targets. 2013;14:768\u201376.","journal-title":"Curr Drug Targets"},{"key":"1737_CR35","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1038\/npp.2012.93","volume":"37","author":"P Zhong","year":"2012","unstructured":"Zhong P, Wang W, Yu F, Nazari M, Liu X, Liu Q. Phosphodiesterase 4 inhibition impairs cocaine-induced inhibitory synaptic plasticity and conditioned place preference. Neuropsychopharmacology. 2012;37:2377\u201387.","journal-title":"Neuropsychopharmacology"},{"key":"1737_CR36","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11515-016-1424-0","volume":"11","author":"CM Olsen","year":"2017","unstructured":"Olsen CM, Liu Q, Road P. Phosphodiesterase 4 inhibitors and drugs of abuse: current knowledge and therapeutic opportunities. Front Biol. 2017;11:376\u201386.","journal-title":"Front Biol"},{"key":"1737_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/ijnp\/pyx118","volume":"21","author":"R Satta","year":"2018","unstructured":"Satta R, Certa B, He D, Lasek AW. Estrogen receptor \u03b2 in the nucleus accumbens regulates the rewarding properties of cocaine in female mice. Int J Neuropsychopharmacol. 2018;21:382\u201392.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1737_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/npp.2016.138","volume":"42","author":"NM Mccall","year":"2017","unstructured":"Mccall NM, Kotecki L, Dominguez-lopez S, Marron E. Velasco F De, Carlblom N, et al. Selective ablation of GIRK channels in dopamine neurons alters behavioral effects of cocaine in mice. Neuropsychopharmacology. 2017;42:707\u201315.","journal-title":"Neuropsychopharmacology"},{"key":"1737_CR39","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/npp.2017.24","volume":"42","author":"CA Siciliano","year":"2017","unstructured":"Siciliano CA, Jones SR. Cocaine potency at the dopamine rransporter tracks discrete motivational states during cocaine self-administration. Neuropsychopharmacology. 2017;42:1893\u2013904. https:\/\/doi.org\/10.1038\/npp.2017.24.","journal-title":"Neuropsychopharmacology"},{"key":"1737_CR40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.pharmthera.2014.06.002","volume":"144","author":"A Sadakierska-Chudy","year":"2014","unstructured":"Sadakierska-Chudy A, Frankowska M, Filip M. Mitoepigenetics and drug addiction. Pharmacol Therapeutics. 2014;144:226\u201333. 1","journal-title":"Pharmacol Therapeutics"},{"key":"1737_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol\/Hematol. 2019;136:56\u201363.","journal-title":"Crit Rev Oncol\/Hematol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01737-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01737-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T10:47:39Z","timestamp":1669891659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01737-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01737-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.05.21251228","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"623"}}